Title:
LAG-3 ANTIBODY AND MEDICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/136392
Kind Code:
A1
Abstract:
Disclosed are an LAG-3 antibody and the medical use thereof. The antibody can specifically bind to the extracellular domain of LAG-3 and has excellent affinity and specificity; and the antibody is a functional antibody, and has the activity of blocking the binding of LAG-3 and the ligand MHC II thereof. In addition, the humanized modification of the antibody is further performed, and the present invention provides a method for verifying the function of the antibody. The antibody can treat multiple cancers or immune diseases by regulating human immune functions.
Inventors:
XU YINGQIAN (CN)
CUI DONGBING (CN)
LI GUANYING (CN)
WANG LILI (CN)
LI HAIRONG (CN)
CUI DONGBING (CN)
LI GUANYING (CN)
WANG LILI (CN)
LI HAIRONG (CN)
Application Number:
PCT/CN2020/141475
Publication Date:
July 08, 2021
Filing Date:
December 30, 2020
Export Citation:
Assignee:
SHANGHAI HAILU BIOLOGICAL TECH CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; C12N15/13; C12N15/85
Domestic Patent References:
| WO2017219995A1 | 2017-12-28 |
Foreign References:
| CN110172099A | 2019-08-27 | |||
| CN110343178A | 2019-10-18 | |||
| CN109748963A | 2019-05-14 | |||
| CN110204614A | 2019-09-06 | |||
| CN110305215A | 2019-10-08 | |||
| CN110343179A | 2019-10-18 | |||
| CN110621337A | 2019-12-27 | |||
| CN110606892A | 2019-12-24 | |||
| CN110615840A | 2019-12-27 |
Other References:
YU XIAOJIE, HUANG XIAO, CHEN XIUXIU, LIU JIANFEI, WU CHENGLIN, PU QIAN, WANG YUXIAO, KANG XIAOQIANG, ZHOU LIJUN: "Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy", MABS, LANDES BIOSCIENCE, US, vol. 11, no. 6, 18 August 2019 (2019-08-18), US, pages 1139 - 1148, XP055825981, ISSN: 1942-0862, DOI: 10.1080/19420862.2019.1629239
Attorney, Agent or Firm:
ADVANCE CHINA IP LAW OFFICE (CN)
Download PDF: